Leukotriene modifiers for asthma treatment
dc.contributor.author | Montuschi, P. | en_US |
dc.contributor.author | Peters-Golden, Marc L. | en_US |
dc.date.accessioned | 2011-01-31T17:34:30Z | |
dc.date.available | 2012-02-21T18:47:01Z | en_US |
dc.date.issued | 2010-12 | en_US |
dc.identifier.citation | Montuschi, P.; Peters-Golden, M. L.; (2010). "Leukotriene modifiers for asthma treatment." Clinical & Experimental Allergy 40(12): 1732-1741. <http://hdl.handle.net/2027.42/79154> | en_US |
dc.identifier.issn | 0954-7894 | en_US |
dc.identifier.issn | 1365-2222 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/79154 | |
dc.description.abstract | Leukotrienes (LTs), including cysteinyl LTs (CysLTs) and LTB 4 , are potent lipid mediators that have a role in the pathophysiology of asthma. At least two receptor subtypes for CysLTs, CysLT 1 and CysLT 2 , have been identified. The activation of the CysLT 1 receptor is responsible for most of the pathophysiological effects of CysLTs in asthma, including increased airway smooth muscle activity, microvascular permeability, and airway mucus secretion. LTB 4 might have a role in severe asthma, asthma exacerbations, and the development of airway hyperresponsiveness. CysLT 1 receptor antagonists can be given orally as monotherapy in patients with mild persistent asthma, but these drugs are generally less effective than inhaled glucocorticoids. Combination of CysLT 1 receptor antagonists and inhaled glucocorticoids in patients with more severe asthma may improve asthma control and enable the dose of inhaled glucocorticoids to be reduced while maintaining similar efficacy. The identification of subgroups of asthmatic patients who respond to CysLT 1 receptor antagonists is relevant for asthma management as the response to these drugs is variable. CysLT 1 receptor antagonists have a potential anti-remodelling effect that might be important for preventing or reversing airway structural changes in patients with asthma. This review discusses the role of LTs in asthma and the role of LT modifiers in asthma treatment.Cite this as: P. Montuschi and M. L. Peters-Golden, Clinical & Experimental Allergy , 2010 (40) 1732–1741. | en_US |
dc.format.extent | 188434 bytes | |
dc.format.extent | 3106 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.title | Leukotriene modifiers for asthma treatment | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Microbiology and Immunology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Department of Pharmacology, Faculty of Medicine, Catholic University of the Sacred Heart, Rome, Italy | en_US |
dc.identifier.pmid | 21059119 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/79154/1/j.1365-2222.2010.03630.x.pdf | |
dc.identifier.doi | 10.1111/j.1365-2222.2010.03630.x | en_US |
dc.identifier.source | Clinical & Experimental Allergy | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.